Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2020 / Articles / Oct / Don’t Exclude the Aged
Manufacture Vaccines Clinical Trials COVID-19

Don’t Exclude the Aged

Most clinical trials against COVID-19 exclude the very patients most at risk from the disease

By Stephanie Vine 10/14/2020 0 min read Quick Read (pre 2022)

Share

Despite being at higher risk of severe COVID-19, older adults are in danger of being excluded from more than 50 percent of COVID-19 clinical trials and 100 percent of vaccine trials, according to a review of COVID-19 trials on clinicaltrials.gov (1). The authors evaluated trials based on their risk of excluding adults over 65 years old and found that most trials featured either age cutoffs or broad, unspecified exclusions.

Although they acknowledge that some exclusion will always be necessary, the authors argue that enrollment of greater numbers of older adults in clinical trials is possible with advance preparation, staff training, and aging expertise. Senior author Sharon Inouye, Director of the Aging Brain Center in the Hinda and Arthur Marcus Institute for Aging Research at Hebrew SeniorLife, believes that many of the exclusion criteria are “not well-justified, and appear to be more for expediency or convenience of the trialists.”

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. BKI Helfand et al., JAMA Intern Med, [Epub ahead of print] (2020). DOI: 10.1001/jamainternmed.2020.5084

About the Author(s)

Stephanie Vine

Making great scientific magazines isn’t just about delivering knowledge and high quality content; it’s also about packaging these in the right words to ensure that someone is truly inspired by a topic. My passion is ensuring that our authors’ expertise is presented as a seamless and enjoyable reading experience, whether in print, in digital or on social media. I’ve spent fourteen years writing and editing features for scientific and manufacturing publications, and in making this content engaging and accessible without sacrificing its scientific integrity. There is nothing better than a magazine with great content that feels great to read.

More Articles by Stephanie Vine

False

Advertisement

Recommended

False

Related Content

Understanding the H5N1 Threat
Vaccines Drug Discovery
Understanding the H5N1 Threat

February 3, 2025

4 min read

With new cases of avian influenza appearing, what does this mean for global health and what are drug developers doing about it?

Peter Marks Resigns from FDA
Standards & Regulation Profession Vaccines Advanced Medicine
Peter Marks Resigns from FDA

April 1, 2025

3 min read

Resignation letter states: “truth and transparency” around vaccines are not desired by Health Secretary RJK Jr. “Rather he wishes subservient confirmation of his misinformation and lies.”

The Shingles Vaccine and Dementia
Drug Discovery Translational Science Vaccines
The Shingles Vaccine and Dementia

April 10, 2025

2 min read

Studies have suggested that the RZV shingles vaccine can lower the risk of dementia; GSK is now investigating further

Robert F. Kennedy Jr Nomination Advances
Standards & Regulation Vaccines
Robert F. Kennedy Jr Nomination Advances

February 6, 2025

2 min read

Senate committee votes in favor of the nomination; full Senate vote will be next

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.